But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost immediately.
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...
In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback